Charles Schwab Investment Management Inc. Acquires 59,648 Shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)

Charles Schwab Investment Management Inc. lifted its stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) by 46.0% in the third quarter, Holdings Channel.com reports. The fund owned 189,413 shares of the company’s stock after purchasing an additional 59,648 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Cyclerion Therapeutics were worth $1,152,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in shares of Cyclerion Therapeutics by 14.7% in the second quarter. Russell Investments Group Ltd. now owns 27,766 shares of the company’s stock worth $163,000 after acquiring an additional 3,557 shares during the period. Bank of America Corp DE raised its position in Cyclerion Therapeutics by 46.9% during the second quarter. Bank of America Corp DE now owns 15,639 shares of the company’s stock valued at $93,000 after purchasing an additional 4,994 shares in the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in Cyclerion Therapeutics during the second quarter valued at about $60,000. Goldman Sachs Group Inc. raised its position in Cyclerion Therapeutics by 68.7% during the second quarter. Goldman Sachs Group Inc. now owns 31,195 shares of the company’s stock valued at $184,000 after purchasing an additional 12,706 shares in the last quarter. Finally, TD Asset Management Inc. raised its position in Cyclerion Therapeutics by 55.9% during the third quarter. TD Asset Management Inc. now owns 39,500 shares of the company’s stock valued at $240,000 after purchasing an additional 14,158 shares in the last quarter. 50.16% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts recently issued reports on CYCN shares. ValuEngine downgraded Cyclerion Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 1st. BidaskClub upgraded Cyclerion Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, September 17th.

In other news, insider Mark G. Currie sold 20,107 shares of Cyclerion Therapeutics stock in a transaction that occurred on Monday, December 28th. The shares were sold at an average price of $3.01, for a total transaction of $60,522.07. Following the completion of the sale, the insider now owns 251,648 shares of the company’s stock, valued at $757,460.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andreas Busch purchased 125,000 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were bought at an average cost of $2.53 per share, with a total value of $316,250.00. The disclosure for this purchase can be found here. Insiders own 10.70% of the company’s stock.

CYCN opened at $3.06 on Friday. The firm has a market cap of $103.92 million, a P/E ratio of -1.03 and a beta of 2.23. Cyclerion Therapeutics, Inc. has a 12 month low of $2.08 and a 12 month high of $8.96. The stock has a 50-day moving average of $3.09 and a 200 day moving average of $4.67.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.03). Cyclerion Therapeutics had a negative net margin of 2,322.42% and a negative return on equity of 105.55%. The company had revenue of $0.40 million for the quarter.

Cyclerion Therapeutics Profile

Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases.

See Also: What are the components of an earnings report?

Want to see what other hedge funds are holding CYCN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cyclerion Therapeutics, Inc. (NASDAQ:CYCN).

Institutional Ownership by Quarter for Cyclerion Therapeutics (NASDAQ:CYCN)

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.